Table 2. Distribution of Clinicopathologic Characteristics of Women Diagnosed With Breast Cancer.
| Variable | N (%) |
|---|---|
| Median age, y (range) | 46 (24-92) |
| Progesterone receptor statusa | |
| Negative | 78 (75.7) |
| Positive | 25 (24.3) |
| Estrogen receptor statusb | |
| Negative | 76 (73.8) |
| Positive | 27 (26.2) |
| HER2 biomarkerc | |
| Negative | 83 (80.6) |
| Positive | 20 (19.4) |
| Graded | |
| 1 | 6 (6.1) |
| 2 | 41 (41.4) |
| 3 | 52 (52.5) |
| Subtype | |
| HER2− and ER− and PR− | 58 (56.3) |
| HER2+ and ER− and/or PR+/PR− | 18 (17.5) |
| HER2− and ER+ and/or PR+/PR− | 19 (18.4) |
| HER2+ and ER+ and PR+ | 8 (7.8) |
Abbreviations: ER, estrogen receptor; HER2 human epidermal growth factor receptor 2/glioblastoma; PR, progesterone receptor.
a
One patient missing estrogen receptor expression staining.
b
One patient missing progesterone receptor expression staining.
c
One patient missing HER2 staining.
d
Five patients missing tumor grade assessment.